ClinicalTrials.gg
RecruitingNCT05004727PAMPAUpdated Mar 30, 2026

Multi-Center PAMPA Study

A Phase 4 interventional study of Guselkumab and Placebo in Psoriasis, sponsored by NYU Langone Health. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by NYU Langone Health · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.

Planned enrollment
13th of 29
176 · median 120
Started
2022
with 1 other
Phase 4
10 of 29
6 open now
Registered
19th of 29
by date

Among the 29 studies testing guselkumab in Psoriasis, this one is the 13th largest by planned enrollment, is one of 2 that started in 2022, is one of 10 in phase 4, and was the 19th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing guselkumab in Psoriasis, or all of them as a file.
02

Study summary

This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care.

The primary objective of the proposed trial will be to test the hypothesis that a prolonged, unresolved skin inflammation coupled with musculoskeletal power-doppler ultrasound (MSKPDUS) abnormalities driven by IL-23 increase the risk for transition into PsA and that an intervention that targets one of these pivotal molecules (i.e., Guselkumab) will:

  1. Diminish MSKPDUS findings at 24 weeks, and
  2. Significantly reduce or prevent the emergence of synovio-enthesial phenotype at year 2.
03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years old or older;
  2. Both male \& female;
  3. Psoriasis diagnosis (per dermatologist) for at least 2 years (in at least 30% of participants);
  4. Willing and able to provide ;
  5. Fulfillment of HR-PsO criteria (Psoriasis (PsO) patients will meet the definition of HR if they fulfill the following criteria: a) PsO duration >2 years and Psoriasis Body Surface Area (BSA) >3% and positive imaging findings in MSKPDUS defined as a RM-PsASon score of >3.36

Exclusion criteria

Exclusion Criteria:

  1. Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam;
  2. Current systemic medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever);
  3. RA seropositivity (mid-high RF/ACPA titers);
  4. Current active ;
  5. History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development
  6. Conditions where initiation of guselkumab is prohibited in the prescribing information, including active infection and untreated latent tuberculosis;
  7. Known to the study agent.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    Guselkumab + Topicals (GUS)

    Drug: Guselkumab

  • Placebo comparator
    Placebo + Topicals (PBO)

    Drug: Guselkumab · Drug: Placebo

  • No intervention
    Standard-of-Care Therapy (SOC)

    In this third, non-randomized arm, patients would continue treatment with topical therapy or UVB, as part of our ongoing natural history of disease registries. This arm will include participants fulfilling RM-PsASon criteria but also those that do not (to serve as "negative" controls).

Interventions

  • Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).

  • DrugPlacebo

    • Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).

06

What researchers measure

Primary outcomes

  1. Change in Musculoskeletal, Power Doppler Ultrasound (MSK-PDUS) Composite Score

    Score is defined by the ultrasound (General Electric Logiq E9 or E10) equipment, not calculated through a scale.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percentage of Patients Transitioning to Psoriatic Arthritis (PsA) by Modified CASPAR Criteria at Year 2

    To meet CASPAR criteria for diagnosis of PsA, a participant must have inflammatory articular disease (joint, spine, entheseal or dactyitic) and at least 3 points from the following: 1. Evidence of current psoriasis (2pts), personal history of psoriasis (2pts), family history (1pt) 2. Typical psoriatic nail dystrophy including onycholysis, pitting, and hyperkeratosis observed on current physical examination (1pt) 3. A negative test result for the presence of rheumatoid factor by any method except latex (1pt) 4. Either current dactylitis, defined as swelling of an entire digit, or a history of dactylitis recorded by a rheumatologist (1pt) 5. Radiographic evidence of juxta-articular new bone formation appearing as ill-defined ossification near joint margins (but excluding osteophyte formation) on plain radiographs of the hand or foot (1pt) The eCRF will autopopulate the total number of points. If the total score ≥ 3, the participant meets criteria for PsA diagnosis.

    Time frame: Year 2

  2. Percentage of Patients Transitioning to Psoriatic Arthritis (PsA) by Modified CASPAR Criteria at Year 1

    To meet CASPAR criteria for diagnosis of PsA, a participant must have inflammatory articular disease (joint, spine, entheseal or dactyitic) and at least 3 points from the following: 1. Evidence of current psoriasis (2pts), personal history of psoriasis (2pts), family history (1pt) 2. Typical psoriatic nail dystrophy including onycholysis, pitting, and hyperkeratosis observed on current physical examination (1pt) 3. A negative test result for the presence of rheumatoid factor by any method except latex (1pt) 4. Either current dactylitis, defined as swelling of an entire digit, or a history of dactylitis recorded by a rheumatologist (1pt) 5. Radiographic evidence of juxta-articular new bone formation appearing as ill-defined ossification near joint margins (but excluding osteophyte formation) on plain radiographs of the hand or foot (1pt) The eCRF will autopopulate the total number of points. If the total score ≥ 3, the participant meets criteria for PsA diagnosis.

    Time frame: Year 1

  3. Severity of PsA at the time of synovio-entheseal development

    Severity will be categorized as mild, moderate, or severe.

    Time frame: Year 2

  4. Change in the ultrasound composite score of synovitis

    Graded from 0-3 as absent, mild, moderate or severe according to images of a reference atlas (Hammer HB 2011). PD signal: 0=no PD-signal, 1=up to three single or two confluent signals, 2=less than half of the visible intracapsular area and 3=half or more of the visible intracapsular area covered by PD-signals.

    Time frame: Baseline, week 24

  5. Change in Madrid Sonographic Enthesis Index (MASEI) Score

    MASEI: Structure is considered pathological (score=1) if there is a loss of fibrillar pattern, hypoechoic aspect, or fusiform thickening of the entheses. Erosions are defined as a cortical breakage with a step-down contour defect at the attachment of entheses at bone and graded with 0=absent or 3=present. Fascia and tendon thickness are measured at the point of maximal thickness on the bony insertion and graded with 0=normal or 1=thickened according to the reference values of the MASEI index. Enthesophytes are defined as calcifications at the entheses insertions into bone and graded with 0=absent, 1=small calcification, 2=clear presence of enthesophyte/calcification, 3= large calcifications or ossifications. PD-signals within entheses are scored with 0=absent or 3=present. Bursitis is investigated at the level of distal patellar tendon (infrapatellar bursitis) and the level of Achilles tendon insertion (retrocalcaneal bursitis) and graded with 0=absent and 1=present.

    Time frame: Baseline, week 24

  6. Psoriasis Body Surface Area (BSA)

    The total BSA affected by plaque-type psoriasis will be estimated from the percentages of areas affected, including head, trunk, upper limbs and lower limbs. The following calculations will be done: each reported percentage will be multiplied by its respective body region corresponding factor (head = 0.1, trunk = 0.3, upper limbs = 0.2, lower limbs = 0.4). The resulting four percentages will be added up to estimate the total BSA affected by psoriasis.

    Time frame: Week 24

  7. Achieved IGA mod 2011 Score

    Score 0 - Clear - No signs of psoriasis. Post-inflammatory hyperpigmentation may be present Score 1 - Almost clear - Normal to pink coloration of lesions; no thickening; no to minimal focal scaling Score 2 - Mild disease - Pink to light red coloration; just detectable to mild thickening; predominantly fine scaling Score 3 - Moderate disease - Dull bright red, clearly distinguishable erythema; clearly distinguishable to moderate thickening; moderate scaling Score 4 - Severe disease - Bright to deep dark red coloration; severe thickening with hard edges; severe / coarse scaling covering almost all or all lesions

    Time frame: Week 24

  8. Change in Functional Assessment of Chronic Illness Therapy (FACIT) Scale

    FACIT consists of 13 statements regarding fatigue (e.g., "I feel fatigued", "I feel weak all over", "I feel tired", etc.). Items are scored as follows: 4=not at all, 3=a little bit, 2=somewhat, 1=quite a bit; 0=very much, EXCEPT items #7 and 8 which are reversed scored. Total score range is 0-52. A score of less than 30 indicates severe fatigue. The higher the score, the better the quality of life.

    Time frame: Week 24

  9. Change in EuroQol-5D (EQ-5D) Score

    The scale measures how good or bad one's health is on the day of the questionnaire. Total score is 0-100; the higher the score, the better the health (0 = worst health one can imagine, 100 = best health one can imagine)

    Time frame: Baseline, Week 24

  10. Change in EuroQol-5D (EQ-5D) Score

    The scale measures how good or bad one's health is on the day of the questionnaire. Total score is 0-100; the higher the score, the better the health (0 = worst health one can imagine, 100 = best health one can imagine)

    Time frame: Baseline, Year 2

  11. Change in International Dermatology Outcome Measures - Musculoskeletal -8 (IDEOM-MSK-8) Score

    IDEOM-MSK-8 is a short questionnaire that allows people with MSK conditions to report their symptoms and quality of life in a standardized way. The total range of score is 0-56; the higher the score, the better the MSK health status. In order to calculate the total score, the numbers next to the boxes that the participant has ticked on the questionnaire form is added up.

    Time frame: Baseline, Week 24

  12. Change in Ultrasound (US) Score

    Score is defined by the ultrasound (General Electric Logiq E9 or E10) equipment, not calculated through a scale.

    Time frame: Baseline, Week 24

  13. Proportion of participants who achieved ≥ 50% improvement in US score at 24 weeks

    Assessed using ultrasound results.

    Time frame: Up to Week 24

07

Study locations

5 of 5 sites recruiting
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • Jeffrey Sparks, MD · Contact
    • Joseph Merola, MD, MMSc · Principal investigator
  • NYU Langone Health
    New York, New York 10016, United States
    Recruiting
    • Jose Scher, MD · ContactJose.Scher@nyulangone.org
    • Stephanie Eichman, EdD · ContactStephanie.Eichman@nyulangone.org
    • Jose Scher, MD · Principal investigator
    • Andrea Neimann, MD, MSCE · Sub investigator
    • Jonathan Samuels, MD · Sub investigator
    • Rebecca Haberman, MD, MSCI · Sub investigator
    • Michael Toprover, MD · Sub investigator
    • Andrea Troxel, ScD · Sub investigator
    • Jiyuan Hu, PhD · Sub investigator
  • University of Rochester Medical Center (URMC)
    Rochester, New York 14623, United States
    Recruiting
    • Christopher Ritchlin, MD, MPH · Contact
    • · ContactChristopher_Ritchlin@urmc.rochester.edu
    • Francisco Tausk, MD · Sub investigator
    • Ralf Thiele, MD · Sub investigator
    • Christopher Ritchlin, MD, MPH · Principal investigator
  • Memorial University
    St. John's, Newfoundland and Labrador A1C 5B8, Canada
    Recruiting
    • Wayne Gulliver, MD · Contactdrgulliver@newlabresearch.com
    • Proton Rahman, MD · Sub investigator
    • Wayne Gulliver, MD, FRCPC · Principal investigator
  • Women's College Research Institute, University of Toronto
    Toronto, Ontario M5S 1B2, Canada
    Recruiting
    • Lihi Eder, MD PhD · Contactlihi.eder@wchospital.ca
    • Lihi Eder, MD PhD · Principal investigator
    • Vincent Piguet, MD PhD · Sub investigator
    • Jensen Yeung, MD · Sub investigator
08

References and documents

Publications

  • Haberman RH, MacFarlane KA, Catron S, Samuels J, Blank RB, Toprover M, Uddin Z, Hu J, Castillo R, Gong C, Qian K, Piguet V, Tausk F, Yeung J, Neimann AL, Gulliver W, Thiele RG, Merola JF, Ogdie A, Rahman P, Chakravarty SD, Eder L, Ritchlin CT, Scher JU. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. 2022 Dec 23;12(12):e063650. doi: 10.1136/bmjopen-2022-063650. PubMed 36564123 ↗

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to jose.scher@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Dec 2026, 58 months after the start.

Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 58 months is above that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2021
First posted
Aug 13, 2021
StartActual
Feb 16, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Nov 2, 2028
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05004727
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Aug 13, 2021
Start date
Feb 16, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Nov 2, 2028 (estimated)
Last update
Mar 30, 2026

Study contacts

Jose Scher, MD
Contact
Jose.Scher@nyulangone.org
6465017400
Stephanie Eichman
Contact
Stephanie.Eichman@nyulangone.org
Jose Scher, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion